Diagnostic firms say FDA made a crucial error in judgment in a 2008 guidance that has blocked the way for more point-of-care testing; now they hope to rally labs, physician groups and patient organizations into a coalition to convince the agency to change course.
The guidance in question addressed standards for achieving a waiver for a test under the Clinical Laboratory Improvement Amendments, which allows the assay to be used by more rudimentary laboratories,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?